The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of chronic use of proton pump inhibitors with an increased risk of immune checkpoint inhibitor-induced colitis in renal cell carcinoma.
 
Roy Elias
No Relationships to Disclose
 
Jianyi Yin
No Relationships to Disclose
 
Lan Peng
No Relationships to Disclose
 
Alana Christie
No Relationships to Disclose
 
Nisa Kubiliun
No Relationships to Disclose
 
James Brugarolas
Consulting or Advisory Role - Arrowhead Pharmaceuticals; Calithera Biosciences; Exelixis
Research Funding - Arrowhead Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Non-invasive PET tracer to evaluate HIF2alpha (Inst); Patent of HIF-2 biomarker (Inst); Patent pertaining HIF2a resistance mutations (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Hans J. Hammers
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - ARMO BioSciences; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; exelixis; Lilly; Merck; Novartis; Pfizer; Surface Oncology
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Novartis; Pfizer